secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001140361-25-041293
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys receives second $500k FemBloc order from Kebomed for Europe
-------------------------------------------------------------------

- Order valued at ~$500k for commercial launch of FemBloc in France and Benelux region.
- Kebomed, a leading distributor, placed the order following Femasys' recent entry into Spain.
- FemBloc is a non-surgical permanent contraceptive using a patented polymer to occlude fallopian tubes.
- CEO Kathy Lee-Sepsick cited strategic partnerships driving international expansion and shareholder value.
- No anesthesia, incisions, or recovery time required; addresses unmet need in reproductive health.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125041293/0001140361-25-041293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125041293/ef20058658_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer